share_log

Arcutis Biotherapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Edwards Larry Todd

Arcutis Biotherapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Edwards Larry Todd

Arcutis Biotherapeutics | 4:持股变动声明-高管 Edwards Larry Todd
美股SEC公告 ·  10/04 04:56

Moomoo AI 已提取核心信息

Larry Todd Edwards, the Senior Vice President and Chief Commercial Officer of Arcutis Biotherapeutics, completed a sale of company stock on October 2, 2024. The transaction involved the disposal of 3,725 shares of common stock at a price of $10.0122 per share, resulting in a total sale value of $37,295.45. Following the sale, Edwards holds a total of 136,635 shares in the company. The sale was conducted in the open market, reflecting a direct ownership transaction.
Larry Todd Edwards, the Senior Vice President and Chief Commercial Officer of Arcutis Biotherapeutics, completed a sale of company stock on October 2, 2024. The transaction involved the disposal of 3,725 shares of common stock at a price of $10.0122 per share, resulting in a total sale value of $37,295.45. Following the sale, Edwards holds a total of 136,635 shares in the company. The sale was conducted in the open market, reflecting a direct ownership transaction.
Arcutis Biotherapeutics的高级副总裁兼首席商业官Larry Todd Edwards于2024年10月2日完成了公司股票的交易。该交易涉及以每股10.0122美元的价格处置3725股普通股,总销售金额为37295.45美元。销售后,Edwards持有公司的136635股。此次销售是在公开市场上进行的,反映了直接的所有权交易。
Arcutis Biotherapeutics的高级副总裁兼首席商业官Larry Todd Edwards于2024年10月2日完成了公司股票的交易。该交易涉及以每股10.0122美元的价格处置3725股普通股,总销售金额为37295.45美元。销售后,Edwards持有公司的136635股。此次销售是在公开市场上进行的,反映了直接的所有权交易。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息